~Strengthens strategic collaboration with DifGen to expand its complex generics portfolio in the US~

Bengaluru: Alembic Pharmaceuticals Limited (“Alembic”) reported its consolidated financial results for the second quarter and half year ended 30th September, 2026. The company further announced the expansion of its strategic collaboration with DifGen Pharmaceuticals (“DifGen”) to grow its complex generics portfolio in the US.

Financial Highlights for Q2 FY27

  • Revenue from operations increased by 36% YoY to Rs. 2603 Cr.
  • EBITDA up by 78% YoY to Rs. 578 Cr, margin at 22%
  • Profit After Tax at Rs. 335 Cr, up 81% YoY

Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Our US business delivered an exceptional performance, driven by strong volume growth and new launches, while India regained momentum as Ex-US and API continued their growth trajectories. In India Branded, improving momentum in chronic therapies is strengthening the quality of growth, while in US Branded, we are encouraged by the traction building across our existing portfolio. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders.”

Operational Highlights

India Branded Business

  • India Branded Business delivered 14% YoY growth, reaching Rs 725 Cr. in revenue for the quarter.
  • Gynecology, Cardiology, Gastrology and Ophthalmology registered robust growth.
  • Animal Health continued its growth momentum with 23% growth for the quarter.

International Business

  • US Formulations grew by 77% to Rs. 1003 Cr.
  • 3 launches in the US market during the quarter.
  • Ex-US grew by 12% to Rs. 440 Cr.
  • 1 ANDA approval received during the quarter, 245 cumulative ANDA approvals.

API Business

  • API business grew by 39% to Rs. 436 Cr.

The summary of Revenue from Operations is as under:

                                                                                                          (Rs in Cr.)

ParticularsQ2 FY26Q2 FY27% ChangeH-1 FY26H-1 FY27% Change
Formulations      
India63972514%1238136710%
USA566100377%1089178164%
Ex-US39244012%71982314%
API31443639%57578236%
Total1910260336%3621475331%

Alembic expands strategic collaboration with DifGen

Building on their existing relationship, including the joint venture in Canada, the expanded collaboration combines DifGen’s development and US manufacturing capabilities with Alembic’s established US commercial platform. DifGen will lead development, regulatory, manufacturing and supply activities, while Alembic will manufacture select products and commercialise the portfolio in the US.

Key highlights of the collaboration:

  • Broad, differentiated complex generics portfolio: portfolio of 20+ differentiated products across injectable, transdermal, ophthalmic, oral and other complex dosage forms addressing an aggregate reference market of ~US$5 billion.
  • Higher value opportunities and faster market access: portfolio includes open (FTF) opportunities, potential Day 1 launches and products with limited expected competition.
  • Near term revenue visibility with potential to scale: initial launches are expected from FY28, providing near-term revenue visibility and a platform for progressively increasing contribution to the US business as the broader portfolio is commercialised over the next few years.
  • US manufacturing optionality: reserves capacity for Alembic at DifGen’s US facilities, with a framework to progressively build US manufacturing capacity for select dosage forms.

Commenting on the collaboration, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “This collaboration further strengthens our complex generics franchise in the US. The portfolio expands Alembic’s exposure to differentiated opportunities, particularly in transdermal systems, complex injectables and other specialised dosage forms. Importantly, the collaboration provides near-term commercial opportunities and access to US manufacturing capabilities. We believe this is a capital efficient way to deepen our pipeline, strengthen the quality, and sustainability of Alembic’s US business growth and create long-term value for our stakeholders.”